![conference banner](/images/conference-banner.jpeg)
Abstract
Inflammation is essential for atherogenesis, and many inflammatory markers have been analyzed for their association with short- and long-term outcome in patients with manifestations of coronary artery disease. C-reactive protein (CRP) plasma levels increase in patients with acute coronary syndrome (ACS). CPR is an important prognostic marker in ACS. Although CRP will remain over time a useful marker, the role and implications of increased plasma concentrations of other acute phase proteins (APPs), such as alpha-1-antitrypsin (A1AT), alpha-1 glycoprotein (A1GP), haptoglobin (HG), ceruloplasmin (CP), and C3c and C4 complement fraction, in patients with ACS are still not completely defined. Controversy is the role of statins and other drugs on inflammatory markers. This review summarizes the experimental and clinical evidence regarding the role, and the biological and clinical significance of these APPs in ACS. Furthermore, biological and clinical significance of Pentraxin 3 (PTX3), a member of the pentraxin superfamily, are discussesed.
Keywords: Acute coronary syndrome, acute myocardial infarction, acute phase reactants, acute phase proteins, atherosclerosis, inflammation-sensitive plasma proteins
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Volume: 10 Issue: 4
Author(s): Michele Correale, Antonio Totaro, Silvia Abruzzese, Matteo Di Biase and Natale Daniele Brunetti
Affiliation:
Keywords: Acute coronary syndrome, acute myocardial infarction, acute phase reactants, acute phase proteins, atherosclerosis, inflammation-sensitive plasma proteins
Abstract: Inflammation is essential for atherogenesis, and many inflammatory markers have been analyzed for their association with short- and long-term outcome in patients with manifestations of coronary artery disease. C-reactive protein (CRP) plasma levels increase in patients with acute coronary syndrome (ACS). CPR is an important prognostic marker in ACS. Although CRP will remain over time a useful marker, the role and implications of increased plasma concentrations of other acute phase proteins (APPs), such as alpha-1-antitrypsin (A1AT), alpha-1 glycoprotein (A1GP), haptoglobin (HG), ceruloplasmin (CP), and C3c and C4 complement fraction, in patients with ACS are still not completely defined. Controversy is the role of statins and other drugs on inflammatory markers. This review summarizes the experimental and clinical evidence regarding the role, and the biological and clinical significance of these APPs in ACS. Furthermore, biological and clinical significance of Pentraxin 3 (PTX3), a member of the pentraxin superfamily, are discussesed.
Export Options
About this article
Cite this article as:
Correale Michele, Totaro Antonio, Abruzzese Silvia, Di Biase Matteo and Daniele Brunetti Natale, Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date, Cardiovascular & Hematological Agents in Medicinal Chemistry 2012; 10 (4) . https://dx.doi.org/10.2174/187152512803530298
DOI https://dx.doi.org/10.2174/187152512803530298 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer
Current Pharmaceutical Design Is there any Additional Prognostic Value of Central Blood Pressure Wave Forms Beyond Peripheral Blood Pressure?
Current Pharmaceutical Design Overexpression of a Modified Amaranth Protein in Escherichia coli with Minimal Media and Lactose as Inducer
Recent Patents on Biotechnology CD44 - a New Cardiovascular Drug Target or Merely an Innocent Bystander?
Cardiovascular & Hematological Disorders-Drug Targets Difference in the Influence of the Lipid Profile as a Coronary Risk Factor in Patients with and Without Diabetes Mellitus
Vascular Disease Prevention (Discontinued) Synthetic Sustained Gene Delivery Systems
Current Topics in Medicinal Chemistry Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Targeting the Role of Lipoprotein (a) in Stroke
Cardiovascular & Hematological Disorders-Drug Targets Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension
Current Hypertension Reviews Advances in Anoctamin 1: A Potential New Drug Target in Medicinal Chemistry
Current Topics in Medicinal Chemistry Nanoparticles: A Promising Therapeutic Approach in Atherosclerosis
Current Drug Delivery Hypotensive Effect of Hydroalcoholic Ziziphus jujuba Extract on Normotensive Rats
Current Nutrition & Food Science Morphology of Atherosclerotic Plaque: Its Feature by Imaging Study
Current Pharmaceutical Design New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Current Drug Therapy The Innate Immune System and Cardiovascular Disease in ESKD: Monocytes and Natural Killer Cells
Current Vascular Pharmacology Selenium, an Ambivalent Factor in Diabetes? Established Facts, Recent Findings and Perspectives
Current Nutrition & Food Science